Related Experiment Video
Updated: May 17, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
A Thomas1, A Rajan, A Lopez-Chavez
1Medical Oncology Branch, National Cancer Institute, Bethesda, 20892, USA.
Abstract:
Although tumor molecular-profile-directed therapy appears promising in early clinical studies, there are many practical challenges to its successful clinical application in non-small-cell lung cancer (NSCLC). These challenges may be broadly classified as those relating to tumor (heterogeneity), tissue (acquisition and processing), testing (assays for molecular profiling) and trials (clinical evaluation of molecular markers and drugs). Strategies to overcome these challenges include (i) understanding the biological basis of tumor heterogeneity and of carcinogenesis in the large subset of patients with no currently evident driver events; (ii) technological advances in minimally invasive acquisition of tumor and next-generation sequencing (NGS) which would enable single-platform analysis of molecular alterations in limited tissue at a reasonable turnaround time (TAT); (iii) deliberation in early stages of drug development as well as clinical trial design to identify, validate and assess the clinical utility of biomarkers in conjunction with drugs and (iv) collaboration to improve understanding of and accrual to trials enrolling patients with rare molecular alterations.
Insights
Targeted therapy for non-small-cell lung cancer (NSCLC) shows promise but faces challenges in tumor biology, tissue handling, testing, and clinical trials. Overcoming these requires advances in technology, trial design, and collaboration for personalized medicine.
Area of Science:
- Oncology
- Genomics
- Clinical Trials
Background:
- Tumor molecular-profile-directed therapy offers potential for non-small-cell lung cancer (NSCLC).
- Significant practical challenges impede its widespread clinical application.
Purpose of the Study:
- To identify and categorize challenges in applying molecular-profile-directed therapy in NSCLC.
- To propose strategies for overcoming these clinical application barriers.
Main Methods:
- Categorization of challenges into tumor, tissue, testing, and trial-related issues.
- Review of current strategies and future directions for molecular profiling in NSCLC.
Main Results:
- Key challenges include tumor heterogeneity, tissue acquisition/processing, assay limitations, and clinical trial design.
- Proposed solutions involve understanding tumor biology, technological advances (e.g., next-generation sequencing), biomarker validation, and collaborative trial enrollment.
Conclusions:
- Addressing challenges in tumor biology, diagnostics, and clinical trials is crucial for advancing personalized medicine in NSCLC.
- Technological innovation and collaborative efforts are essential for successful implementation of molecular-profile-directed therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenomics: Identification of New Drug Targets
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...